Drug intelligence / Profile preview

NVG-333

Development stage: Unknown
Lead developer: NovalGen
Modality: Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NVG-333 is an investigational autologous CAR-T cell therapy developed by Novalgen. It is a next-generation ROR1-targeting armored CAR-T cell with inducible secretion of a dual payload in response to tumor cell engagement (biCAR). The drug acts as an antagonist of the inactive tyrosine-protein kinase transmembrane receptor ROR1 and is being explored for the treatment of neoplasms. As of April 2025, its highest development status is at the Discovery stage[1][2].

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)

Beyond the preview

Go deeper on NVG-333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVG-333.

Explore the full profile